BERKELEY, Calif. and MAINZ, Germany, Oct. 15, 2025 — (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic firm specializing in the early detection of cancer, today announced its forthcoming participation in the 2025 Maxim Growth Summit, scheduled for October 22-23, 2025, at The Hard Rock Hotel NYC.
This esteemed gathering brings together prominent industry figures, innovators, and leading institutions to explore the latest trends and breakthroughs across various sectors. Keynote speakers will include Larry Kudlow (Broadcaster, Fox News) and Christopher Ruddy (CEO, Newsmax Media). The conference will also feature roundtable discussions with CEOs from both small and large companies, facilitated by Maxim Research Analysts. These discussions will span a multitude of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, and drones, among others.
Mainz Biomed plans to conduct one-on-one meetings with institutional investors during the event, as well as with senior Maxim analysts.
For additional details and the complete agenda of the Maxim Growth Summit, please visit .
Stay updated by following us:
About Mainz Biomed NV
Mainz Biomed develops molecular genetic diagnostic solutions ready for market that address life-threatening conditions. The Company’s primary product is ColoAlert®, an accurate, non-invasive, and user-friendly diagnostic test for the early identification of colorectal cancer. ColoAlert® is currently available throughout Europe. The Company is presently conducting its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study aimed at securing U.S. regulatory approval. Mainz Biomed’s product pipeline also includes PancAlert, an early-stage screening test for pancreatic cancer, which relies on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit or connect with us on , and .
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
For investor inquiries, please contact
Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking statements” as defined by the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terms such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that forecast or indicate future events or trends, or are not statements of historical fact. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. Consequently, caution must be exercised when relying on forward-looking statements. Due to both known and unknown risks, actual results may diverge substantially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to achieve projected development and related objectives; (ii) changes in applicable laws or regulations; (iii) the impact of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties detailed herein, as well as those risks and uncertainties discussed periodically in other reports and public filings with the Securities and Exchange Commission (the “SEC”) by the Company.
